Results 171 to 180 of about 114,702 (262)

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source

Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor. [PDF]

Kidney Int Rep, 2021
Nie G, Sun L, Sun B, Zhu H, Li J, Xing C, Zhang B.   +6 more
europepmc   +1 more source

A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context. [PDF]

JAAD Case Rep, 2021
Van Rooij N, Johnston J, Mortimore R, Robertson I.   +3 more
europepmc   +1 more source

A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. [PDF]

Br J Haematol, 2022
Song Y, Sun M, Qi J, Xu W, Zhou J, Li D, Li J, Qiu L, Du C, Guo H, Huang J, Tang Z, Ou Y, Wu B, Yu Y, Zhu J.   +15 more
europepmc   +1 more source

A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor. [PDF]

Br J Haematol
Heß G, Eyre TA, Jen MH, Zhang J, Goebel B, Abhyankar S, Dreyling M.   +6 more
europepmc   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies. [PDF]

Br J Clin Pharmacol
Kumagai Y, Fujita T, Maeda M, Yamamoto A, Amano H.   +4 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitor in non-IgM lymphoplasmacytic lymphoma: a case report and literature review. [PDF]

J Clin Exp Hematop
Ito K, Hirano K, Sekiguchi N.
europepmc   +1 more source

Scedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy. [PDF]

J Hematol
Dalmazzo M, Padrini M, Camerlo S, Rosati G, Busana TT, Nicoli P, Perotto F, Davicco L, Caironi P, De Gobbi M, Morotti A.   +10 more
europepmc   +1 more source

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources

Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. [PDF]

Oncologist
Fernandez Turizo MJ, Kim E, Zhang C, Yankama T, Von Keudell G, Sermer DJ, Mejías-De Jesús C, Asnani A.   +7 more
europepmc   +1 more source